Home › Compound Library › Sofosbuvir/Velpatasvir (Epclusa)

Sofosbuvir/Velpatasvir (Epclusa)

Antiviralprescriptionoral · inferred

Pan-genotypic fixed-dose combination direct-acting antiviral for chronic hepatitis C (all HCV genotypes 1-6). Sofosbuvir 400 mg (NS5B nucleotide polymerase inhibitor, prodrug of active GS-461203) plus velpatasvir 100 mg (NS5A inhibitor). One pill PO once daily with or without food for 12 weeks (with ribavirin in decompensated cirrhosis). Velpatasvir terminal half-life ~17h dominates regimen PK; sofosbuvir's circulating metabolite GS-331007 t1/2 ~27h. Cure rates >95% in treatment-naive non-cirrhotic and compensated cirrhotic patients (ASTRAL-1).

Projected serum levels — 1 pill (≈ 500 mg), once daily

Sofosbuvir/Velpatasvir (Epclusa)
Sofosbuvir/Velpatasvir (Epclusa) modeled serum levels, 1 pill (≈ 500 mg) once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 50 100 150 200 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 1 pill (≈ 500 mg) once daily (oral).

Modeled steady state after ~1 days: peak ≈ 189 mg, trough ≈ 9.7 mg body load. Population-based estimate over 15 days for a reference dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Antiviral
Route modeled
Oral
Model confidence
inferred
Half-life
4.9 h
Common dose
1 pill (≈ 500 mg)
Suggested maximum
1 pill/day
Reference dose range
0.50–1 pill (single dose)
Suggested cadence
once daily

Documented interactions

  • moderate
    Apigenin + Sofosbuvir/Velpatasvir (Epclusa) Transporter inhibition

    Apigenin inhibitor of BCRP may alter Sofosbuvir/Velpatasvir (Epclusa) absorption / distribution

  • moderate
    Carvedilol (Coreg) + Sofosbuvir/Velpatasvir (Epclusa) Transporter inhibition

    Carvedilol (Coreg) inhibitor of P-gp may alter Sofosbuvir/Velpatasvir (Epclusa) absorption / distribution

  • moderate
    CBD (Cannabidiol) + Sofosbuvir/Velpatasvir (Epclusa) Transporter inhibition

    CBD (Cannabidiol) inhibitor of P-gp may alter Sofosbuvir/Velpatasvir (Epclusa) absorption / distribution

  • moderate
    Efavirenz (Sustiva) + Sofosbuvir/Velpatasvir (Epclusa) Transporter induction

    Efavirenz (Sustiva) inducer of P-gp may alter Sofosbuvir/Velpatasvir (Epclusa) absorption / distribution

  • moderate
    Fisetin + Sofosbuvir/Velpatasvir (Epclusa) Transporter inhibition

    Fisetin inhibitor of BCRP may alter Sofosbuvir/Velpatasvir (Epclusa) absorption / distribution

  • moderate
    Ginkgo Biloba (EGb 761) + Sofosbuvir/Velpatasvir (Epclusa) Transporter inhibition

    Ginkgo Biloba (EGb 761) inhibitor of P-gp may alter Sofosbuvir/Velpatasvir (Epclusa) absorption / distribution

Serum checks 28 modeled interaction pairings for sofosbuvir/velpatasvir (epclusa) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Clinical pharmacokinetics of the pan-genotypic sofosbuvir/velpatasvir single-tablet regimen in HCV-infected subjects Mogalian E et al. · Clinical Pharmacokinetics, 2017 DOI

    Clinical PK characterization of sof/vel single-tablet regimen: exposures, velpatasvir ~17h t1/2, and lack of clinically relevant drug interactions from co-formulation.

  2. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection (ASTRAL-1) Feld JJ et al. · New England Journal of Medicine, 2015 DOI

    Pivotal ASTRAL-1 phase 3 trial demonstrating >99% SVR12 with sof/vel 12 weeks across HCV genotypes 1, 2, 4, 5, and 6.

2 published studies referenced in the app, each with a plain-language summary.